Merck To Pay Up To $1.25 Billion For Afferent’s P2X3 Receptor Candidate In Phase 3

Blogging by phone, on the beach, here.

Do go read it all at FierceBiotech — but good news for Kenilworth’s diversifying pipeline efforts:

. . . .Launched in 2009 with backing from Third Rock and Pappas, with Kevin Starr taking the chairman’s role, San Mateo, CA-based Afferent specialized in targeting the P2X3 receptor as a pathway to treating a variety of neurogenic conditions. Hitting this target should damp down a process that oversensitizes certain sensory nerves. . . .

Keep it spinning in good karma, one and all!


There are no comments on this post.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: